α-Synuclein and dopamine metabolism
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
α-Synuclein (α-Syn), a 140-amino-acid protein richly expressed in presynaptic terminals in the central nervous system, has been shown to play a central role in the pathogenesis of Parkinson’s disease. Although the normal functions of α-Syn remain elusive, accumulating evidence shows that the molecule is involved in multiple steps related to dopamine metabolism, including dopamine synthesis, storage, release, and uptake. The regulatory effect of α-Syn on dopamine metabolism is likely to tone down the amount of cytoplasmic dopamine at nerve terminals, thereby limiting its conversion to highly reactive oxidative molecules. Formation of α-Syn protofibrils triggered by factors such as gene mutations and environmental toxins can make the molecule lose its normal functions, leading to disrupted homeostasis of dopamine metabolism, increased cytoplasmic dopamine levels, and enhanced oxidative stress in dopaminergic neurons. The enhanced oxidative stress will, in turn, exacerbate the formation of α-Syn protofibrils and drive the neurons into a vicious cycle, which will finally result in the selective degeneration of the dopaminergic neurons associated with Parkinson’s disease.
Chan P., Tanner C.M., Jiang X., and Langston J.W. (1998) Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson’s disease. Neurology 50, 513–514.PubMed
Chan P., Jiang X., Forno L.S., Di Monte D.A., Tanner C.M., and Langston J.W. (1998) Absence of mutations in the coding region of the alphasynuclein gene pathologically proven Parkinson’s disease. Neurology 50, 1136–1137.PubMed
Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature (London) 388, 839–840.CrossRef
Baba M., Nakajo S., Tu P.H., et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879–884.PubMed
Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L., and Masliah E. (1998) Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am. J. Pathol. 152, 367–372.PubMed
Lee H.J. and Lee S.J. (2002) Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277, 48,976–48,983.
Lavedan C. (1998) The synuclein family. Genome Res. 8, 871–880.PubMed
Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., and Lansbury P.T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alphasynuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571–576.PubMedCrossRef
Ma Q.L., Chan P., Yoshii M., and Uéda K. (2003) Alpha-synuclein aggregation and neurodegenerative diseases. J. Alzheimer’s Dis. 5, 139–148.
Mouradian M.M. (2002) Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58, 179–185.PubMed
Youdim M.B. (2003) What have we learnt from cDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson’s disease? J. Neural Transm. 65(Suppl.), 73–88.
Graham D.G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol. Pharmacol. 14, 633–643.PubMed
George J.M. (2002) The synucleins. Genome Biol. 3, 1–6.
Maroteaux L., Campanelli J.T., and Scheller R.H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804–2815.PubMed
Uëda K., Fukushima H., Masliah E., et al. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 11,282–11,286.CrossRef
Perrin R.J., Woods W.S., Clayton D.F., and George J.M. (2000) Interaction of human alpha-synuclein and Parkinson’s disease variants with phospholipids. J. Biol. Chem. 275, 34,393–34,398.CrossRef
Kahle P.J., Neumann M., Ozman L., et al. (2000) Subcellular localization of wild-type and Parkinson’s disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365–6373.PubMed
Irizarry M.C., Kim T.W., McNamara M., et al. (1996) Characterisation of the precursor of the non-Aβ component of senile plaques (NACP) in the human central nervous system. J. Neuropathol. Exp. Neurol. 55, 889–895.PubMed
Murphy D.D., Rueter S.M., Trojanovski J.Q., and Lee V.M.-Y. (2000) Synucleins are developmentally expressed, and α-Synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214–3220.PubMed
Ostrerova N., Petrucelli L., Farrer M., et al. (1999) Alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 5782–5791.PubMed
Cabin D.E., Shimazu K., Murphy D., et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22, 8797–8807.PubMed
Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H.K., and Brundin P. (2002) Effect of mutant alpha-synuclein on dopamine home-ostasis in a new human mesencephalic cell line. J. Biol. Chem. 277, 38,884–38,894.CrossRef
Ahn B.H., Rhim H., Kim S.Y., et al. (2002) α-Synuclein interacts with phospholipase D isozymes and inhibits pervandate induced phospholipase D activation in human embryonic kidney 293 cells. J. Biol. Chem. 277, 12,334–12,342.
Jensen P.H., Hojrup P., Hager H., et al. (1999) Alpha-synuclein binds to T and stimulates the protein kinase A-catalysed τ phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274, 25,481–25,489.
Pronin A.N., Morris A.J., Surguchov A., and Benovic J.L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26,515–26,522.CrossRef
Schmidt A., Wolde M., Thiele C., et al. (1999) Endophilin I mediates synaptic vesicle formation by transfer arachidonate to lysophosphatidic acid. Nature (London) 401, 133–141.CrossRef
Jensen P.H., Islam K., Kenney J., Nielsen M.S., Power J., and Gai W.P. (2000) Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments. J. Biol. Chem. 275, 21,500–21,507.
Sharma N., Hewett J., Ozelius L.J., et al. (2001) A close association of torsin A and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am. J. Pathol. 159, 339–344.PubMed
Wersinger C., Prou D., Vernier P., and Sidhu A. (2003) Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. E-pub. (14), 2151–2153.
Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., and Zigmond M.J. (2002) A role for α-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090–3099.PubMed
Sakurada K., Ohshima-Sakurada M., Palmer T.D., and Gage F.H. (1999) Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 126, 4017–4026.PubMed
Barja G. (2000) The flux of free radical attack through mitochondrial DNA is related to aging rate. Aging Clin. Exp. Res. 12, 342–355.
- α-Synuclein and dopamine metabolism
Volume 31, Issue 1-3 , pp 243-254
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press
- Additional Links
- Parkinson’s disease
- oxidative stress
- Industry Sectors
- Author Affiliations
- 1. Department of Neurobiology and the Sino-Japan Joint Laboratory on Neurodegenerative Diseases, Beijing Institute of Geriatrics, Xuanwu Hospital of Capital University of Medical Sciences, Beijing, China
- 2. Institute for Hypoxia Medicine, Capital University of Medical Science, Beijing, China
- 3. Department of Neural Plasticity, Tokyo Institute of Psychiatry, Tokyo, Japan